Investing in Alimera Sciences (NASDAQ:ALIM) a Year Ago Would Have Delivered You a 68% Gain
Processa Pharmaceuticals Appoints Russell Skibsted as CFO
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Alimera Sciences, Inc. Buyout
Alliance Global Partners Downgrades Alimera Sciences to Neutral From Buy, Adjusts Price Target to $5.50 From $8
Express News | Alimera Sciences Inc : Alliance Global Partners Cuts to Neutral From Buy
Craig-Hallum Upgrades Alimera Sciences(ALIM.US) to Buy Rating, Raises Target Price to $8
Maxim Group Downgrades Alimera Sciences(ALIM.US) to Hold Rating
Express News | Alimera Sciences Inc : Maxim Group Cuts to Hold From Buy
Alimera Sciences Analyst Ratings
Express News | Alimera Sciences Inc : H.c. Wainwright Cuts to Neutral From Buy
H.C. Wainwright Downgrades Alimera Sciences(ALIM.US) to Hold Rating, Maintains Target Price $6
Nasdaq Records Worst Session Since April With Nvidia Plunging 7%: Dow Jones Sees Modest Gains Amid Mixed Market Close
Express News | Alimera Sciences Inc : Craig-Hallum Cuts to Hold From Buy; Cuts Target Price to $5.50 From $8
Craig-Hallum Downgrades Alimera Sciences(ALIM.US) to Hold Rating, Announces Target Price $5.5
Trending Stocks Today: Agrify Shoots up 96.92%
Alimera Sciences Shares Rally Almost 80% After Buyout Offer from ANI Pharmaceuticals
Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher
Shareholder Alert: Ademi LLP Investigates Whether Alimera Sciences, Inc. Has Obtained a Fair Price for Its Public Shareholders
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal
Express News | Alimera Sciences Shares Hit Over 1-1/2 Year High After ANI Pharmaceuticals to Buy Co for $5.5/Shr, Last up 76.8%